quinidine

QUINIDINE:

KWIN-i-deen

quiNIDine gluconate: KWIN-i-deen GLUE-con-ate

quiNIDine sulfate: KWIN-i-deen SUL-fate

Classifications ⬆ ⬇

Therapeutic Classification: antiarrhythmics (class IA)

Indications ⬆ ⬇

REMS

Restoration and maintenance of sinus rhythm in patients with atrial fibrillation or flutter.
Prevention of recurrent ventricular arrhythmias.
Treatment of malaria.

Action ⬆ ⬇

Decrease myocardial excitability.
Slow conduction velocity.

Therapeutic effects:

Suppression of arrhythmias.

Pharmacokinetics ⬆ ⬇

Absorption: Bioavailability of oral formulations is 70–80%. Extended-release preparations are absorbed slowly following oral administration.

Distribution: Widely distributed. Cross the placenta; enter breast milk.

Metabolism/Excretion: Metabolized by the liver; 5–20% excreted unchanged by the kidneys.

Half-Life: 6–8 hr (↑ in HF or severe liver impairment).

Time/Action Profile ⬆ ⬇

(antiarrhythmic effects)

ROUTE	ONSET	PEAK	DURATION
PO (sulfate)	30 min	1–1.5 hr	6–8 hr
PO (sulfate-ER)	unknown	4 hr	8–12 hr
PO (gluconate)	unknown	3–4 hr	6–8 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity;
Conduction defects (in the absence of a pacemaker);
Myasthenia gravis.

Use Cautiously in:

HF (dose reduction recommended);
Severe liver disease (dose ↓ recommended);
Hypokalemia or hypomagnesemia (↑ risk of torsades de pointes);
Bradycardia (↑ risk of torsades de pointes);
Renal impairment;
OB: Safety not established; extended-release preparations should not be used in children.

Adv. Reactions/Side Effects ⬆ ⬇

CV: arrhythmias, HYPOTENSION, palpitations, tachycardia, TORSADES DE POINTES

Derm: rash

EENT: blurred vision, diplopia, mydriasis, photophobia, tinnitus

GI: abdominal cramping, anorexia, diarrhea, nausea, vomiting, drug-induced hepatitis

Hemat: AGRANULOCYTOSIS, hemolytic anemia, thrombocytopenia

Neuro: dizziness, ataxia, confusion, fatigue, headache, syncope, tremor, vertigo

Misc: fever

Interactions ⬆ ⬇

Drug-drug:

May ↑ risk of QT interval prolongation when used with tricyclic antidepressants, erythromycin, clarithromycin, haloperidol, sotalol, or fluoroquinolones.
↑serum digoxin levels and may cause toxicity (dose reduction recommended).
Phenytoin, phenobarbital, carbamazepine, or rifampin may ↑ metabolism and ↓ effectiveness.
Cimetidine, diltiazem, verapamil, amiodarone, ketoconazole, itraconazole, and protease inhibitors↓ metabolism and may ↑ blood levels.
Excretion is delayed and effects ↑ by drugs that alkalinize the urine, including carbonic anhydrase inhibitors, thiazide diuretics, and sodium bicarbonate.
Potentiates the effects of neuromuscular blocking agents and warfarin.
Additive hypotension with antihypertensives, nitrates, and acute ingestion of alcohol.
May ↑ procainamide, haloperidol, mexiletine, or tricyclic antidepressant levels and risk of toxicity.
May antagonize anticholinesterase therapy in patients with myasthenia gravis.
Additive anticholinergic effects may occur with agents having anticholinergic properties (including antihistamines, tricyclic antidepressants).

Grapefruit juice↑ serum levels and effect (avoid concurrent use).
Foods that alkalinize the urine (see Food Sources for Specific Nutrients) may ↑ serum quinidine levels and the risk of toxicity.

Route/Dosage ⬆ ⬇

Quinidine Gluconate (62% Quinidine)

PO (Adults ): 324–972 mg q 8–12 hr.

Quinidine Sulfate (83% Quinidine)

PO (Adults ): Atrial/ventricular arrhythmias: 200–400 mg q 4–6 hr; may be ↑ to achieve therapeutic response (not to exceed 3–4 g/day).
PO (Children ): 6 mg/kg 4–5 times daily.

Availability ⬆ ⬇

Quinidine Gluconate

Quinidine Sulfate

(Generic available)

Extended-release tablets: 324 mg
Tablets: 200 mg; 300 mg
Extended-release tablets: 300 mg
In combination with: dextromethorphan (Nuedexta); see Appendix [not included in this PDA edition].

Assessment ⬆ ⬇

Monitor ECG, pulse, and BP periodically during therapy.

Lab Test Considerations:

Monitor hepatic and renal function, CBC, and serum potassium and magnesium levels periodically during prolonged therapy.

Toxicity and Overdose:

Serum quinidine levels may be monitored periodically during dose adjustment. Therapeutic serum concentrations are 2–6 mcg/mL. Toxic effects usually occur at concentrations >8 mcg/mL.
- Signs and symptoms of toxicity or cinchonism include tinnitus, hearing loss, visual disturbances, headache, nausea, and dizziness. These may occur after a single dose.
- Cardiac signs of toxicity include QRS widening, cardiac asystole, ventricular ectopic beats, idioventricular rhythms (ventricular tachycardia, ventricular fibrillation), paradoxical tachycardia, and torsades de pointes.

Implementation ⬆ ⬇

Do not confuse quinidine with quinine.
PO: Administer with a full glass of water on an empty stomach either 1 hr before or 2 hr after meals for faster absorption. If GI irritation becomes a problem, may be administered with or immediately after meals. Extended-release preparations should be swallowed whole; do not break, crush, or chew.

IV Administration:

IV: Use only clear, colorless solution.
Intermittent Infusion: Diluent: Dilute 800 mg of quinidine gluconate (10 mL) in 50 mL of D5W. Infusion is stable for 24 hr at room temperature or 48 hr if refrigerated.Concentration: 16 mg/mL.
Rate: Administer quinidine gluconate at a rate not to exceed 0.25 mg/kg/min. Administer via infusion pump to ensure accurate dose. Rapid administration may cause peripheral vascular collapse and severe hypotension.

Patient/Family Teaching ⬆ ⬇

Instruct patient to take medication around the clock, exactly as directed, even if feeling well. Take missed doses as soon as remembered if within 2 hr; if remembered later, omit. Do not double doses.
Instruct patient or family member on how to take pulse. Advise patient to report changes in pulse rate or rhythm to health care professional.
May cause dizziness or blurred vision. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
Inform patient that quinidine may cause increased sensitivity to light. Dark glasses may minimize this effect.
Advise patient to inform health care professional of medication regimen prior to treatment or surgery.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
Advise patient to consult health care professional if symptoms of cinchonism, rash, or dyspnea occur or if diarrhea is severe or persistent.
Advise patient to carry identification at all times describing disease process and medication regimen.
Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
Emphasize the importance of routine follow-up exams to monitor progress.

Evaluation/Desired Outcomes ⬆ ⬇

Decrease or cessation of cardiac arrhythmia.
Resolution of malarial infection.

US Brand Names ⬆ ⬇

quiNIDine gluconate: ~~Quinaglute,~~

quiNIDine sulfate: ~~Quinidex~~

Code ⬆

NDC Code

0185- Eon Labs, Inc.
- 0185-1047- Quinidine Sulfate
  - 0185-1047-01- 100 TABLET in 1 BOTTLE (0185-1047-01)

0185- Eon Labs, Inc.
- 0185-4346- Quinidine Sulfate
  - 0185-4346-01- 100 TABLET in 1 BOTTLE (0185-4346-01)

section name header

Pronunciation ⬇